Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QUVEH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20230256114A1 ADC (DAR4) 1
|
|||||
| Synonyms |
US20230256114A1 ADC (DAR4) 1
Click to Show/Hide
|
|||||
| Organization |
BIONECURE THERAPEUTICS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-Trop
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.49 nM | Positive TROP2 expression (TROP2+++/++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.51 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.54 nM | Moderate TROP2 expression (TROP2++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.68 nM | Low TROP2 expression (TROP2+) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Colon adenocarcinoma | Colo205 cells | CVCL_0218 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.01 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2.88 nM | Positive TROP2 expression (TROP2+++/++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 4.88 nM | Moderate TROP2 expression (TROP2++) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 56.42 nM | Low TROP2 expression (TROP2+) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Colon adenocarcinoma | Colo205 cells | CVCL_0218 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Negative TROP2 expression (TROP2-) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Negative TROP2 expression (TROP2-) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Negative TROP2 expression (TROP2-) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Negative TROP2 expression (TROP2-) | ||
| Method Description |
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||